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Abstract 
Background: Severe COVID-19 infection results in a systemic inflammatory response (SIRS). This SIRS response shares 
similarities to the changes observed during the peri-operative period that are recognised to be associated with the 
development of multiple organ failure.
Methods: Electronic patient records for patients who were admitted to an urban teaching hospital during the initial 
7-week period of the COVID-19 pandemic in Glasgow, U.K. (17th March 2020—1st May 2020) were examined for 
routine clinical, laboratory and clinical outcome data. Age, sex, BMI and documented evidence of COVID-19 infection 
at time of discharge or death certification were considered minimal criteria for inclusion.
Results: Of the 224 patients who fulfilled the criteria for inclusion, 52 (23%) had died at 30-days following admis-
sion. COVID-19 related respiratory failure (75%) and multiorgan failure (12%) were the commonest causes of death 
recorded. Age ≥ 70 years (p < 0.001), past medical history of cognitive impairment (p ≤ 0.001), previous delirium 
(p < 0.001), clinical frailty score > 3 (p < 0.001), hypertension (p < 0.05), heart failure (p < 0.01), national early warning 
score (NEWS) > 4 (p < 0.01), positive CXR (p < 0.01), and subsequent positive COVID-19 swab (p ≤ 0.001) were associ-
ated with 30-day mortality. CRP > 80 mg/L (p < 0.05), albumin < 35 g/L (p < 0.05), peri-operative Glasgow Prognostic 
Score (poGPS) (p < 0.05), lymphocytes < 1.5  109/l (p < 0.05), neutrophil lymphocyte ratio (p ≤ 0.001), haematocrit 
(< 0.40 L/L (male)/ < 0.37 L/L (female)) (p ≤ 0.01), urea > 7.5 mmol/L (p < 0.001), creatinine > 130 mmol/L (p < 0.05) and 
elevated urea: albumin ratio (< 0.001) were also associated with 30-day mortality.
On multivariate analysis, age ≥ 70 years (O.R. 3.9, 95% C.I. 1.4–8.2, p < 0.001), past medical history of heart failure (O.R. 
3.3, 95% C.I. 1.2–19.3, p < 0.05), NEWS > 4 (O.R. 2.4, 95% C.I. 1.1–4.4, p < 0.05), positive initial CXR (O.R. 0.4, 95% C.I. 0.2–
0.9, p < 0.05) and poGPS (O.R. 2.3, 95% C.I. 1.1–4.4, p < 0.05) remained independently associated with 30-day mortality.
Among those patients who tested PCR COVID-19 positive (n = 122), age ≥ 70 years (O.R. 4.7, 95% C.I. 2.0—11.3, 
p < 0.001), past medical history of heart failure (O.R. 4.4, 95% C.I. 1.2–20.5, p < 0.05) and poGPS (O.R. 2.4, 95% C.I. 1.1–5.1, 
p < 0.05) remained independently associated with 30-days mortality.
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Background
As of 27th May 2020, approximately 5.7 million peo-
ple worldwide are known to have been infected with 
COVID-19 coronavirus and more than 350,000 have died 
[1]. The severity of this viral disease for an individual is 
associated with a widespread perturbation of immune, 
physiological and metabolic parameters [2, 3]. These 
whole body changes could be considered characteris-
tic of a systemic inflammatory response to tissue injury 
and it has been long recognised that a large and ongoing 
systemic inflammatory response is associated with the 
development of multiple organ failure and infective dis-
ease [4, 5].
One of the cardinal signs of severe COVID-19 infec-
tion is a marked systemic inflammatory response [2]. 
This response bears striking similarity to the systemic 
inflammatory response experienced by patients under-
going major elective surgical resections for cancer [6, 
7]. Indeed, the systemic inflammatory response and the 
associated metabolic stress has been most well charac-
terised in major elective surgery, where the relationship 
between the magnitude of the post-operative systemic 
inflammatory response and the development of post-
operative complications is now well recognised, as is 
the effect of patient comorbidity on this relationship [8, 
9]. Such work has informed therapeutic manoeuvres 
including minimally invasive surgery, pre-operative opti-
misation (e.g. anaesthesia, nutrition and steroids) and 
enhanced recovery protocols.
The aim of the present study was to examine whether 
routinely collected clinicopathological characteristics of 
patients with COVID-19 on admission were informa-
tive on the immune and metabolic stress experienced by 
patients with COVID-19 and whether such characteris-
tics were informative on subsequent outcome.
Patients and methods
Electronic patient records for patients who attended the 
Emergency Department (ED) and Acute Assessment 
Unit (AAU) at Glasgow Royal Infirmary (GRI), Glasgow, 
U.K., during the initial 7-week period of the COVID-19 
pandemic in Glasgow city (17th March 2020–1st May 
2020) were examined for routine clinical, laboratory and 
clinical outcome data. GRI is a university teaching hos-
pital that serves an urban population with a high burden 
of socio-economic deprivation and offers the full spec-
trum of adult acute receiving specialties to patients over 
16  years old. In line with NHS policy, this study was 
approved by the NHS Greater Glasgow and Clyde Cal-
dicott guardian. The study protocol (GN20AE307) was 
approved by the North West England—Preston research 
ethics committee (20/NW/0336) and registered with 
clinicaltrials.gov (NCT04484545).
Patients displaying clinical signs or reporting symp-
toms consistent with possible COVID-19 infection (as 
defined by Health Protection Scotland) [10] at the time 
of presentation to ED and AAU were assessed for inclu-
sion in the study. Patients who were reported by a board 
certified radiologist to have radiological changes charac-
teristic of COVID-19 infection reported on chest X-ray 
(CXR) or CT thorax, were assessed for inclusion in the 
study. Patients who were admitted with other conditions 
and tested polymerase chain reaction (PCR) positive 
following admission were also included in the analysis. 
SARS-CoV-2 PCR testing was performed on all patients 
included in the sample, however only 122 of the 264 
patients who satisfied HPS criteria for clinical diagnosis 
of SARS-CoV-2 and were admitted to hospital, subse-
quently had the diagnosis confirmed with positive SARS-
CoV-2 PCR test. Age, sex, BMI and documented (clinical, 
radiological or PCR) evidence of COVID-19 infection at 
time of discharge or death certification were considered 
minimal criteria for inclusion.
As per routine clinical practice in the Emergency 
Department and Acute Assessment Area at GRI, patients 
were scored on the National Early Warning Score 
(NEWS) at presentation to triage. NEWS is a validated 
score of severity of physiological derangement that allo-
cates a score (0–3) to six clinical parameters (pulse 
rate, blood pressure, respiratory rate, oxygen satura-
tions, requirement for supplemental oxygen and level 
of responsiveness (alert (A), responding to verbal (V), 
painful (P) stimuli and unresponsive (U) (AVPU scale)) 
[11]. NEWS determines the triage category and level of 
immediate treatment that is required at the time of pres-
entation, and the interval to re-administering the NEWS 
scoring tool according to the score achieved (i.e. the 
severity of physiological derangement). NEWS > 4 and > 7 
are considered to indicate moderately severe and severe 
physiological derangement respectively.
Conclusion: Age ≥ 70 years and severe systemic inflammation as measured by the peri-operative Glasgow Prognos-
tic Score are independently associated with 30-day mortality among patients admitted to hospital with COVID-19 
infection.
Keywords: COVID-19, Systemic inflammatory response (SIRS), C-reactive protein (CRP), Albumin, Peri-operative 
glasgow prognostic score (poGPS), Neutrophil lymphocyte ratio (NLR), 30-day mortality, Host inflammatory response
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Age was grouped as less than 40  years, 40–49  years, 
50–59  years, 60–69  years, 70–79  years and 80  years 
and older. Age categories were further simplified 
to < / ≥ 70 years (see Tables 3, 4, 5). Social deprivation was 
defined by the Scottish Indices of Multiple Deprivation 
2019 based on individual home postcode. Ethnicity was 
classified as White, Mixed, Asian, Black, or other ethnic 
group. Frailty was assessed using the Clinical Frailty Scale 
(CFS) [12, 13].
Admission serum C-reactive protein (CRP), albumin 
and differential blood cell counts were categorised using 
local reference intervals. Neutrophil/lymphocyte ratio 
(NLR) and the peri-operative Glasgow Prognostic Score 
(poGPS) were calculated as outlined in Tables 1, 2 [6, 14, 
15]. The neutrophil lymphocyte ratio (NLR) is a validated 
prognostic scoring system that has been used in a vari-
ety of clinical settings. It utilises two components of the 
differential white cell count that are routinely measured 
in patients admitted to the general hospital setting. How-
ever, studies utilising the NLR in sepsis and peri-opera-
tive prognostic scores have used a variety of thresholds, 
making inter-study extrapolation of results difficult. For 
this study, thresholds of NLR ≤ 3, > 3—< 5 and ≥ 5 have 
been chosen, indicating mild, moderate and severe sys-
temic inflammatory response respectively [16].
Statistical analysis
Autobiographical data, clinicopathological data and hae-
matological/biochemical results were presented as cat-
egorical variables. Categorical variables were analysed 
using χ2 test for linear-by-linear association, or χ2 test for 
2-by-2 tables.
Associations between autobiographical data, clinico-
pathological characteristics, haematological/biochemical 
results and survival were analysed using univariate and a 
multivariate backward conditional approach. A p < 0.05 
was applied to inclusion at each step in the multivariate 
analysis.
A convenience sampling strategy was adopted based on 
the patients admitted during the study period; therefore a 
formal sample size calculation was not performed. Miss-
ing data were excluded from analysis on a variable-by-
variable basis. Two-tailed p values < 0.05 were considered 
statistically significant. Statistical analysis was performed 
using SPSS software version 25.0. (SPSS Inc., Chicago, IL, 
USA).
Results
Of the 359 patients who attended Glasgow Royal Infirmary 
and satisfied HPS criteria for categorising as a possible 
COVID -19 related presentation, 241 patients fulfilled the 
criteria for inclusion with age, sex, BMI and documented 
evidence of COVID-19 infection at discharge or death cer-
tification. Seventeen patients were re-admitted and these 
were excluded from the analysis at second admission leav-
ing 224 patients to be included in the analysis. The clin-
icopathological characteristics at presentation are shown 
in Table  3. The majority of patients were ≥ 70  years old 
(88%), male (55%), were not obese (57%) and were socioec-
onomically deprived (SE groups 1 and 2, 64%). The major-
ity of patients were living independently in their own home 
(85%) and of white Scottish (93%) ethnicity. The majority 
of patients did not have comorbid disease including hyper-
tension (60%), heart failure (90%) or type 2 diabetes (77%) 
and were not frail (54%). The median BMI was 29·0 kg/m2, 
with 33% of individuals having a BMI of less than 26 kg/
m2, and 25% exceeding a BMI of 35.0 kg/m2.
The median temperature of patients was 37.0  °C (IQR 
36.3–38.0  °C). The majority of patients had a tempera-
ture < 37.5  °C (65%) and 14% of patients had a tempera-
ture < 36  °C. On admission the majority of patients had 
moderately severe or  severe physiological derangement 
(NEWS score > 4) (60%) and had radiological changes 
characteristic of COVID-19 infection reported on chest 
X-ray (59%).
Of the laboratory analysis at presentation, the major-
ity of patients had evidence of a systemic inflammatory 
response as evidenced by an elevated CRP > 80  mg/L 
(51%) and NLR (80%). The majority of patients had bili-
rubin (88%), alkaline phosphatase (91%), AST (54%), 
ALT (79%), glucose (53%), urea (67%), creatinine (90%), 
sodium (86%), potassium (80%), MCV (84%) and platelets 
(80%) within the laboratory reference range.
Table 1 Calculation of  the  Neutrophil Lymphocyte Ratio 
(NLR)
Neutrophil Lymphocyte Ratio (NLR): Ratio SIRS severity
Neutrophil count: lymphocyte count  < 3 Mild
Neutrophil count: lymphocyte count 3–5 Moderate
Neutrophil count: lymphocyte count  > 5 Severe
Table 2 Peri-operative Glasgow Prognostic Score (poGPS)
peri-operative Glasgow Prognostic Score 
(poGPS)
Score SIRS severity
C-reactive protein ≤ 150 mg/l and Albu-
min ≥ 25 g/l
0 Mild
C-reactive protein > 150 mg/l and Albu-
min ≥ 25 g/l
1 Moderate
C-reactive protein ≤ 150 mg/l and Albu-
min < 25 g/l
1 Moderate
C-reactive protein > 150 mg/l and Albu-
min < 25 g/l
2 Severe
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Table 3 Univariate analysis of  clinicopathological characteristics of  patients admitted with  symptoms of  COVID-19 
(n = 224)
Alive (n = 172) Dead (n = 52) p-value
Age (< / ≥ 70 years) 124/48 19/33  < 0.001
Sex (male/female) 91/81 33/19 0.181
BMI (< 20; ≥ 20–29; ≥ 30 kg/m2) 13/85/74 4/25/23 0.867
SIMD (1 (most)–6 (least) deprived) 81/31/17/23/1/19 24/4/7/11/0/6 0.685
Ethnicity (1–5) 159/0/7/2/3 50/0/0/0/2 0.774
Living circumstances (0–3) 151/11/7/3 39/2/8/3 0.008
Past Medical History
 Hypertension (y/n) 63/109 28/24 0.027
 Heart failure (y/n) 12/160 11/41 0.003
 T1DM (y/n) 2/170 0/52 0.436
 T2DM (y/n) 37/135 15/37 0.273
 Chronic renal failure (y/n) 18/154 10/42 0.095
 Cognitive impairment (y/n) 16/156 14/38 0.001
 Previous delirium (y/n) 6/166 10/40  < 0.001
 Frailty score (≤ / > 3) 107/65 14/38  < 0.001
 COPD (y/n) 29/143 12/40 0.311
 Smoker (never/ex/active) 82/70/20 24/27/1 0.428
 Alcohol excess (y/n) 22/150 9/43 0.410
 Liver disease (y/n) 15/157 4/48 0.816
 Hep C (never/previous/active) 167/2/2 51/1/0 0.650
 Active cancer (y/n) 6/166 3/49 0.464
 Asthma (y/n) 42/130 4/48 0.009
 Surgery < 1 yr (y/n) 17/154 4/44 0.277
 Cancer resection (y/n) 1/171 0/52 0.582
Diagnostic criteria
 PCR positive/Clinical Dx/Radiological Dx 74/7/91 37/1/14 0.001
 PCR negative/indeterminate/positive 43/42/83 4/9/39 0.001
 CXR negative/positive 63/107 30/21 0.006
Physiology at presentation
 NEWS (≤ / > 4) 75/96 12/39 0.009
 Delirium (y/n) 14/158 12/36 0.001
Laboratory results at presentation
 CRP (< / ≥ 150 mg/L) 134/37 34/18 0.058
 Albumin (≥ / < 35 g/L) 82/87 15/35 0.021
 poGPS (0/1/2) 130/35/3 32/15/3 0.032
 WCC (< 4.5 / ≥ 4.5—≤ 11.0/ > 11.0 × 109/L) 23/118/30 7/34/11 0.750
 Neutrophils (< / ≥ 7.5 × 109/L) 132/39 34/18 0.088
 Lymphocytes (≥ / < 1.5 × 109/L) 52/118 7/45 0.015
 NLR (< 3/ 3–5 / ≥ 5) 39/46/85 5/9/38 0.004
 Hb (≥ / < 12.0 g/dL) 143/28 38/13 0.142
 MCV (> / ≤ 99 fl) 149/21 40/11 0.102
 Hct (male ≥ / < 0.40) (female ≥ / < 0.37) L/L 126/45 29/23 0.014
 Platelets (≥ / < 150 × 109) 140/30 40/12 0.383
 Sodium (< 133/ ≥ 133– ≤ 146/ > 146 mmol/L) 17/153/2 9/40/3 0.013
 Potassium (< 3.5/ ≥ 3.5– ≤ 5.5/ > 5.5 mmol/L) 13/142/2 5/36/0 0.822
 Mg (≥ / < 0.75 mmol/L) 33/60 8/28 0.148
Urea (≤ / > 7.5 mmol/L) 125/47 24/28  < 0.001
Creatinine (≤ / > 130 umol/L) 159/13 43/9 0.039
AST (≤ / > 40 IU) 96/55 24/16 0.678
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At 30-days following admission, 52 patients had died 
and the mortality rate was 23%. COVID-19 related 
respiratory failure (75%) and multiorgan failure (12%) 
were the commonest causes of death recorded. The 
relationship between 30-day mortality and clinico-
pathological characteristics are shown in Table 3. Death 
following admission for COVID-19 was associated 
with age ≥ 70  years (p < 0.001), past medical history of 
cognitive impairment (p ≤ 0.001), previous delirium 
(p < 0.001), clinical frailty score > 3 (p < 0.001), hyper-
tension (p < 0.05), heart failure (p < 0.01), NEWS > 4 
(p < 0.01), positive CXR (p < 0.01), and subsequent posi-
tive COVID-19 swab (p ≤ 0.001). Death was also asso-
ciated with CRP > 80  mg/L (p < 0.05), albumin < 35  g/L 
(p < 0.05), poGPS (p < 0.05), lymphocytes < 1.5  109/l 
(p < 0.05), neutrophil lymphocyte ratio (p ≤ 0.001), 
haematocrit (< 0.40 L/L (male)/ < 0.37 L/L (female)) 
(p ≤ 0.01), urea > 7.5  mmol/L (p < 0.001), creati-
nine > 130 mmol/L (p < 0.05) and elevated urea: albumin 
ratio (< 0.001).
To determine which admission parameters were 
independently associated with death within 30  days, 
binary logistic regression analysis was carried out (see 
Table 4). On analysis, age ≥ 70 years (O.R. 3.9, 95% C.I. 
1.4–8.2, p < 0.001), past medical history of heart fail-
ure (O.R. 3.3, 95% C.I. 1.2–19.3, p < 0.05), NEWS > 4 at 
presentation (O.R. 2.4, 95% C.I. 1.1–4.4, p < 0.05), posi-
tive initial CXR (O.R. 0.4, 95% C.I. 0.2–0.9, p < 0.05) and 
poGPS (O.R. 2.3, 95% C.I. 1.1–4.4, p < 0.05) remained 
independently associated with death.
Among those patients who tested PCR COVID-19 
positive (n = 122), age ≥ 70  years (O.R. 4.7, 95% C.I. 
2.0–11.3, p < 0.001), past medical history of heart fail-
ure (O.R. 4.4, 95% C.I. 1.2–20.5, p < 0.05) and poGPS 
(O.R. 2.4, 95% C.I. 1.1–5.1, p < 0.05) remained indepen-
dently associated with 30-days mortality (see Table 5).
Discussion
The results of the present study show that, on admission 
and using routine clinical measures, there was a wide-
ranging perturbance of clinicopathological parameters 
in patients with COVID-19. In particular, heart failure 
and activation of the systemic inflammatory response 
were independently associated with death at 30  days. 
Therefore, it would appear that, in addition to the current 
anti-viral therapeutic targets, the host systemic inflam-
matory response may be a legitimate therapeutic target 
in patients presenting to Emergency Departments with 
COVID-19.
The results of the present study are consistent with a 
number of other small studies [17–19] from Asia that 
have reported the usefulness of markers of the systemic 
inflammatory response to risk stratify patients with 
COVID-19. In particular, the NLR has been previously 
reported to have prognostic value in these patients [14, 
20, 21]. For example, Liu et al. reported in a prospective 
validation study that NLR was a predictor of critical ill-
ness in 61 patients with PCR confirmed COVID-19 infec-
tion [21]. Similarly, Yang et  al. reported in a randomly 
selected cohort of 69 non-severe and 24 severe cases 
that NLR > 3.3 was independently associated with “more 
severe illness” (HR 2.46; 95% CI 1.98–4.57; p < 0.05) 
[14]. Lagunas-Rangel reported a meta-analysis of NLR 
and lymphocyte-CRP ratio that included 5 studies from 
mainland China, comprising 828 patients, which con-
cluded that increased NLR and low lymphocyte-CRP 
ratios, reflecting an enhanced inflammatory process, 
may suggest a poor prognosis [22]. The present study, 
Table 3 (continued)
Alive (n = 172) Dead (n = 52) p-value
ALT (≤ / > 56 IU) 136/33 41/9 0.810
ALP (≤ / > 130 IU) 155/14 49/2 0.294
Bilirubin (≤ / > 17 mmol/L) 151/18 45/6 0.823
Glucose (≤ / > 7 mmol/L) 96/51 22/20 0.128
Lactate (< / ≥ 2 mmol/L) 43/21 17/12 0.426
HCO3 (≥ / < 22 mmol/L) 29/7 14/4 0.813
PT (≤ / > 13 s) 94/ 50 24/17 0.429
APPT (≤ / > 38 s) 133/8 36/3 0.642
Living circumstances: 0 = independent, 1 = sheltered accommodation, 2 = care home, 3 = nursing home
Ethnicity: White = 1, Mixed = 2, Asian = 3, Black = 4, Other ethnic groups or missing = 5
poGPS peri-operative Glasgow prognostic score, NLR neutrophil lymphocyte ratio
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Table 4 Binary logistic regression analysis of  clinicopathological characteristics of  patients admitted with  symptoms 
of COVID-19 (n = 224)
Alive (n = 172) Dead (n = 52) p-value O.R 95% CI p-value
Age (< / ≥ 70 years) 124/48 19/33  < 0.001 3.9 1.4–8.2  < 0.001
Sex (male/female) 91/81 33/19 0.181
BMI (< 20; ≥ 20–29; ≥ 30 kg/m2) 13/85/74 4/25/23 0.867
SIMD (1 (most)–6 (least) deprived) 81/31/17/23/1/19 24/4/7/11/0/6 0.685
Ethnicity (1–5) 159/0/7/2/3 50/0/0/0/2 0.774
Living circumstances (0–3) 151/11/7/3 39/2/8/3 0.008
Past Medical History
 Hypertension (y/n) 63/109 28/24 0.027 ─ ─ 0.229
 Heart failure (y/n) 12/160 11/41 0.003 3.3 1.2–19.3 0.028
 T1DM (y/n) 2/170 0/52 0.436
 T2DM (y/n) 37/135 15/37 0.273
 Chronic renal failure (y/n) 18/154 10/42 0.095
 Cognitive impairment (y/n) 16/156 14/38 0.001
 Previous delirium (y/n) 6/166 10/40  < 0.001
 Frailty score (≤ / > 3) 107/65 14/38  < 0.001
 COPD (y/n) 29/143 12/40 0.311
 Smoker (never/ex/active) 82/70/20 24/27/1 0.428
 Alcohol excess (y/n) 22/150 9/43 0.410
 Liver disease (y/n) 15/157 4/48 0.816
 Hep C (never/previous/active) 167/2/2 51/1/0 0.650
 Active cancer (y/n) 6/166 3/49 0.464
Diagnostic criteria
 PCR positive/Clinical Dx/Radiological Dx 74/7/91 37/1/14 0.001
 PCR negative/indeterminate/positive 43/42/83 4/9/39 0.001
 CXR negative/positive 63/107 30/21 0.006 0.40 0.4–0.9 0.020
Physiology at presentation
 NEWS (≤ / > 4) 75/96 12/39 0.009 2.4 1.1–4.4 0.024
 Delirium (y/n) 14/158 12/36 0.001
Laboratory results at presentation
 CRP (< / ≥ 150 mg/L) 134/37 34/18 0.058
 Albumin (≥ / < 35 g/L) 82/87 15/35 0.021
 poGPS (0/1/2) 130/35/3 32/15/3 0.032 2.2 1.1–4.4 0.024
 WCC (< 4.5 / ≥ 4.5—≤ 11.0 / > 11.0 × 109/L) 23/118/30 7/34/11 0.750
 Neutrophils (< / ≥ 7.5 × 109/L) 132/39 34/18 0.088
 Lymphocytes (≥ / < 1.5 × 109/L) 52/118 7/45 0.015
 NLR (< 3/ 3–5 / ≥ 5) 39/46/85 5/9/38 0.004 – – 0.126
 Hb (≥ / < 12.0 g/dL) 143/28 38/13 0.142
 MCV (> / ≤ 99 fl) 149/21 40/11 0.102
 Hct (male ≥ / < 0.40) (female ≥ / < 0.37) L/L 126/45 29/23 0.014 ─ ─ 0.125
 Platelets (≥ / < 150 × 109) 140/30 40/12 0.383
 Sodium (< 133/ ≥ 133- ≤ 146/ > 146 mmol/L) 17/153/2 9/40/3 0.013
 Potassium (< 3.5/ ≥ 3.5- ≤ 5.5/ > 5.5 mmol/L) 13/142/2 5/36/0 0.822
 Mg (≥ / < 0.75 mmol/L) 33/60 8/28 0.148
 Urea (≤ / > 7.5 mmol/L) 125/47 24/28  < 0.001
 Creatinine (≤ / > 130 umol/L) 159/13 43/9 0.039
 AST (≤ / > 40 IU) 96/55 24/16 0.678
 ALT (≤ / > 56 IU) 136/33 41/9 0.810
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compared with these previous studies, has greater detail 
in the admission clinicopathological characteristics, 
thereby reducing the potential confounding of unmeas-
ured factors. Moreover, it uses a standardised measure of 
the systemic inflammatory response (developed to assess 
the magnitude of the post-operative systemic inflamma-
tory response)—the poGPS [6]. This study is also among 
the first to provide data from a U.K. population.
Data from the present study are also consistent with 
recent reports of an inverse relationship between age 
and BMI among patients with COVID-19 who were 
admitted to the intensive care setting (see Fig.  1) [23]. 
However, contrary to recent reports [24, 25], no signifi-
cant association was found between BMI and mortality 
in the present study. Interestingly, a BMI of 40 kg/m2 or 
higher was identified by the Centre for Disease Control 
and Prevention in the USA as a factor that may increase 
a person’s vulnerability to severe COVID-19 infection 
[26]. Nonetheless, despite the association between a BMI 
in the obese range and established risk factors for severe 
COVID-19 infection, such as type 2 diabetes, hyperten-
sion, and cardiovascular disease [25], data from the pre-
sent study do not support an association with an increase 
in COVID-19 related mortality. The reasons for this are 
not clear. However, the present sample size may not have 
been large enough to detect the effect of obesity. Never-
theless, obesity compared with other physiological and 
inflammatory parameters is likely to have a smaller effect 
and may not provide a useful therapeutic target.
The post-operative systemic inflammatory response 
and the subsequent metabolic stress has been the sub-
ject of continuing interest over the last 40  years. In 
particular, there are well-developed therapeutic strate-
gies to moderate the systemic inflammatory response. 
These include minimising surgical trauma and psycho-
logical distress; the use of anti-inflammatory agents 
(steroids) and antibiotics; fluid optimisation; optimal 
glucose control and nutritional support, to form an 
enhanced recovery strategy [7]. If the present results 
are confirmed, then it may be that using this knowl-
edge to moderate the systemic inflammatory response 
associated with COVID-19 may reduce mortality. 
Indeed, the role of dexamethasone is endorsed by the 
recent positive report from the RECOVERY trial that 
showed a significant survival benefit at 28-days among 
patients who required either invasive mechanical venti-
lation or oxygen alone at randomization but not among 
those receiving no respiratory support [27]. Further-
more, there is emerging evidence of the importance of 
pro-inflammatory cytokines interleukin-6 (IL-6) and 
tumour necrosis factor (TNF-alpha) as predictors of 
mortality in patients with COVID-19 [28] and that IL-6 
blockade appears to be beneficial [29]. Biran et al.have 
recently reported in a retrospective multi-centre obser-
vational study of 764 patients with severe SARS-CoV-2 
infection requiring ICU support that treatment with a 
recombinant monoclonal antibody against the interleu-
kin (IL)-6 receptor, Tocilizumab®, was associated with 
a 25% reduction in hospital-related mortality [29]. Ran-
domised trials are required to confirm these results.
Despite the massive surge in COVID-19 related 
deaths, a relatively small proportion of the overall num-
ber infected have become unwell [1]. However, among 
those who do become unwell, clinical deterioration due 
to cytokine storm can occur with alarming rapidity, and 
mortality is high [18, 30]. The present results are con-
sistent with these results and importantly offer a means 
of routine clinical assessment of an on-going systemic 
inflammatory response and its treatment since pro-
inflammatory cytokine measurements are not routinely 
available from clinical laboratories.
Numerous randomised controlled trails of anti-viral 
agents are ongoing based on the premise that treat-
ing viral infection may benefit patients by reducing 
viral load and aiding recovery. To date, none of these 
studies have reported a significant mortality benefit. 
Therefore, in the absence of such direct intervention 
it may be important to minimise the systemic inflam-
matory response and support host metabolism in line 
with optimal peri-operative care. This strategy has the 
advantage of being part of routine clinical care and may 
complement more aggressive anti-viral strategies.
The present study has a number of limitations. There 
was a relatively small sample size and therefore subject 
to limitations such as sample bias. In addition, the eth-
nic background of the patients within this study was 
Table 4 (continued)
Living circumstances: 0 = independent, 1 = sheltered accommodation, 2 = care home, 3 = nursing home
Ethnicity: White = 1, Mixed = 2, Asian = 3, Black = 4, Other ethnic groups = 5
poGPS peri-operative Glasgow prognostic score, NLR neutrophil lymphocyte ratio
Alive (n = 172) Dead (n = 52) p-value O.R 95% CI p-value
 ALP (≤ / > 130 IU) 155/14 49/2 0.294
 Bilirubin (≤ / > 17 mmol/L) 151/18 45/6 0.823
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Table 5 Binary logistic regression analysis of clinicopathological characteristics of patients admitted who had COVID-19 
PCR + (n = 122)
Living circumstances: 0 = independent, 1 = sheltered accommodation, 2 = care home, 3 = nursing home
Ethnicity: White = 1, Mixed = 2, Asian = 3, Black = 4, Other ethnic groups = 5
poGPS peri-operative Glasgow prognostic score, NLR neutrophil lymphocyte ratio
Alive (n = 83) Dead (n = 39) p-value O.R 95%CI p-value
Age (< / ≥ 70 years) 53/30 12/27  < 0.001 4.7 2.0–11.3 0.001
Sex (male/female) 39/44 16/23 0.219
BMI (< 20; ≥ 20–29; ≥ 30 kg/m2) 5/37/41 3/18/18 0.798
SIMD (1 (least)–6 (most) deprived) 9/1/16/10/21/37 4/0/9/6/2/21 0.959
Ethnicity (1–5) 79/0/3/1/0 37/0/0/0/2 0.441
Living circumstances (0–3) 72/8/2/1 30/0/7/2 0.027
Past Medical History
 Hypertension (y/n) 33/50 20/19 0.233 – – 0.765
 Heart failure (y/n) 4/79 7/32 0.019 4.4 1.1–18.6 0.042
 T1DM (y/n) 1/82 0/39 0.493
 T2DM (y/n) 22/61 10/29 0.920
 Chronic renal failure (y/n) 9/74 8/31 0.152
 Cognitive impairment (y/n) 8/75 12/27 0.003
 Previous delirium (y/n) 3/80 10/28  < 0.001
 Frailty score (≤ / > 3) 53/30 8/31  < 0.001
 COPD (y/n) 11/72 11/28 0.046 – – 0.279
 Smoker 41/35/7 16/22/1 0.833
 Alcohol excess (y/n) 5/78 5/34 0.204
 Liver disease (y/n) 6/77 2/37 0.663
 Hep C (never/previous/active) 82/0/1 39/0/0 0.493
 Active cancer (y/n) 4/79 1/38 0.560
Diagnostic criteria
 CXR negative/positive 38/45 22/16 0.218
Physiology at presentation
 NEWS (≤ / > 4) 36/46 10/29 0.054 ─ ─ 0.146
 Delirium (y/n) 6/77 10/27 0.003
Laboratory results at presentation
 poGPS (0/1/2) 63/16/2 24/11/3 0.063 2.4 1.1–5.1 0.027
 NLR (< 3/ 3–5 / ≥ 5) 21/23/38 5/6/28 0.015 ─ ─ 0.144
 Hb (≥ / < 12.0 g/dL) 65/17 28/10 0.497
 MCV (≤ / > 99 fl) 75/7 30/9 0.028 ─ ─ 0.235
 Hct (male ≥ / < 0.40) (female ≥ / < 0.37) L/L 59/23 23/16 0.155
 Platelets (< 150/ ≥ 150- < 450/ ≥ 450 × 109) 14/67/0 9/30/1 0.452
 Sodium (≤ 133 /134 -145/ ≥ 146 mmol/L) 10/71/2 5/31/3 0.240
 Potassium (< 3.5/ ≥ 3.5 – ≤ 5.3/ > 53 mmol/L) 5/73/0 3/27/0 0.525
 Mg (≥ / < 0.75 mmol/L) 12/3 4/2 0.527
 Urea (≤ / > 7.0 mmol/L) 57/26 17/22 0.008
 Creatinine (≤ / > 130 umol/L) 76/7 34/5 0.450
 AST (≤ / > 40 IU) 48/26 21/28 0.466
 ALT (≤ / > 56 IU) 69/12 33/5 0.810
 ALP (≤ / > 150 IU) 75/6 37/1 0.304
 Bilirubin (≤ / > 17 mmol/L) 78/3 35/3 0.332
 Glucose (≤ / > 7 mmol/L) 40/27 18/12 0.978
 Lactate (< / ≥ 2 mmol/L) 24/6 13/7 0.241
 HCO3 (≥ / < 22 mmol/L) 16/4 9/3 0.744
 PT (≤ / > 13 s) 53/16 19/11 0.169
 APPT (≤ / > 38 s) 67/3 3/26 0.253
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not as diverse as in other population centres globally. 
Furthermore, the level of deprivation was relatively 
high compared to other population centres in the UK. 
However, this study was based on routine clinical meas-
urements and therefore readily subject to confirmation. 
Other less commonly utilised measurements, such 
as LDH and D-dimer have also been reported to have 
prognostic value in patients with COVID-19 infection 
[2]. However, these are recognised to be elevated as part 
of the systemic inflammatory response and may reflect 
the same process. Therefore, further work is required to 
rationalise the use of markers of the systemic inflam-
matory response in patients with COVID-19.
Conclusion
Old age and severe systemic inflammation, as evi-
denced by the post-operative Glasgow Prognostic Score 
(poGPS), were independently associated with 30-day 
mortality in patients admitted to hospital with COVID-
19 infection.
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